ZYVERSA THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $548.23 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-05-13
- ZYVERSA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was $548.23K, a 23.18% increase year-over-year.
- ZYVERSA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was -$349.40K.
- ZYVERSA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $105.11K, a 81.85% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-06-30 was $516.48K, a 131.24% increase year-over-year.
- ZYVERSA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $717.25K, a 414.13% increase from fiscal 2024.
- ZYVERSA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $139.51K, a 37.40% increase from fiscal 2023.
- ZYVERSA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $101.53K.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 1 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 11 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2026-03-31 | $548.23K 10-Q · filed 2026-05-13 | $198.82K derived: sum of 2 quarters · filed 2026-05-13 | $303.94K derived: sum of 3 quarters · filed 2026-05-13 | $820.42K derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2025-12-31 | -$349.40K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$244.29K derived: sum of 2 quarters · filed 2026-03-31 | $272.19K derived: sum of 3 quarters · filed 2026-03-31 | $717.25K 10-K · filed 2026-03-31 | ||
| 2025-09-30 | $105.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $621.60K derived: sum of 2 quarters · filed 2025-11-19 | $1.07M 10-Q · filed 2025-11-19 | $703.33K derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2025-06-30 | $516.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $961.54K 10-Q · filed 2025-08-13 | $598.21K derived: sum of 3 quarters · filed 2026-05-13 | $1.18M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2025-03-31 | $445.06K 10-Q · filed 2026-05-13 | $81.73K derived: sum of 2 quarters · filed 2026-05-13 | $660.78K derived: sum of 3 quarters · filed 2026-05-13 | $884.13K derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | -$363.33K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $215.72K derived: sum of 2 quarters · filed 2026-03-31 | $439.07K derived: sum of 3 quarters · filed 2026-03-31 | $139.51K 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $579.05K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $802.40K derived: sum of 2 quarters · filed 2025-11-19 | $502.84K 10-Q · filed 2025-11-19 | -$518.11K derived: sum of 4 quarters · filed 2025-11-19 | ||
| 2024-06-30 | $223.35K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$76.21K 10-Q · filed 2025-08-13 | -$1.10M derived: sum of 3 quarters · filed 2025-08-13 | -$587.75K derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | -$299.56K 10-Q · filed 2025-05-12 | -$1.32M derived: sum of 2 quarters · filed 2025-05-12 | -$811.11K derived: sum of 3 quarters · filed 2025-05-12 | -$257.28K derived: sum of 4 quarters · filed 2025-05-12 | ||
| 2023-12-31 | -$1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$511.54K derived: sum of 2 quarters · filed 2025-03-27 | $42.28K derived: sum of 3 quarters · filed 2025-03-27 | $101.53K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $509.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.06M derived: sum of 2 quarters · filed 2024-11-14 | $1.12M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $553.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $613.08K 10-Q · filed 2024-08-09 | ||||
| 2023-03-31 | $59.25K 10-Q · filed 2024-05-15 | |||||
| 2022-12-31 | -$715.73K 10-K · filed 2024-03-25 | |||||
| 2022-12-12 | $1.43M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |